76328-94-4

Basic information

• Product Name: 6-chlorohexa-1-en-3-one
• CAS NO: 76328-94-4
• Molecular Weight: 132.59
• Mol File: 76328-94-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 192.3±23.0 °C(Predicted)
• Density: 1.010±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 6-chlorohexa-1-en-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chlorohexa-1-en-3-one(76328-94-4)
• EPA Substance Registry System: 6-chlorohexa-1-en-3-one(76328-94-4)

Safety Data

• Hazardous Substances Data: 76328-94-4(Hazardous Substances Data)

Usage

General Description

6-chlorohexa-1-en-3-one is a chemical compound with the molecular formula C6H9ClO. It is a haloenone, which means it contains a chlorine atom and a ketone group. 6-chlorohexa-1-en-3-one is a yellowish liquid with a distinctive odor and is commonly used in the production of pharmaceuticals and flavoring agents. It is also used as a reagent in organic synthesis and chemical research. 6-chlorohexa-1-en-3-one is considered to have low toxicity, but should still be handled with care and proper safety precautions.

Downstream Products

• 1426535-54-7 3-(4-chlorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 
• 10183-74-1 withasomnine 
• 1314138-13-0 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 
• 174790-35-3 3-bromo-5,6-dihydro-4H-pyrrolo<1,2-b>pyrazole 

Relevant articles and documents

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Dihydropyrrolo[1,2-b]pyrazoles: Withasomnine and related compounds

In the paper we indicate the increasing importance of derivatives containing a dihydropyrrolo[1,2-b]pyrazole (DPP) core. We try to show our synthetic approach based on an improved Kulinkovich method as well as our new synthetic pathway. A complex methodology involving the preparation of substituted DPPs focuses on withasomnine and the synthesis of several structurally related compounds. The developed reaction protocols enable the preparation of the mentioned bicyclic system with broadly diverse substitution. Thus, we are able to prepare systems with aliphatic, aromatic, polyaromatic, heteroaromatic, TMS, and even adamantane substitution with known biologically active properties. The reaction protocol, consisting of two multi-step synthetic pathways, includes Sonogashira and Suzuki-Miyaura cross-coupling reactions, allenyl synthon formation, Kulinkovich cyclopropanation, ring transformations, and nonsymmetrical homoallenyl azines cycloadditions. Moreover, we prepared compounds with a resemblance to other bioactive species: fadrozole, nagstatine, an antitumor agent LY2109761 and a mixed lineage kinase 7 inhibitor DHP-2.

New synthetic route to the alkaloid withasomnine by ring transformation of a functionalized cyclopropanol via the parent pyrrolo[1,2-b]pyrazole

Withasomnine has been prepared by rearrangement of 1-(3-chloropropyl)-cyclopropanol into 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole, followed by bromination and [NiCl2(dppp)]-catalyzed phenylation.